- Data Presented at the International Congress of Parkinson’s Disease and Movement Disorders - The posters presented from Alterity’s bioMUSE study address the need for incorporating biomarkers as a ...
This was a single-arm, interventional-, single-center, open-label prospective study. Patients with a history of probable MSA [15] were enrolled in the study (Table 1). All patients had some ...
MELBOURNE, Australia and SAN FRANCISCO, May 05, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying ...
Orthostatic hypotension is a cardinal feature of multiple-system atrophy. The upright posture provokes syncopal episodes that prevent patients from standing and walking for more than brief periods. We ...
BIRMINGHAM, Ala. – Multiple system atrophy is a rare and fatal neurodegenerative disease, where insoluble inclusions of the protein alpha-synuclein appear in oligodendrocyte cells of the brain. The ...
Company is advancing ATH434 in late-stage clinical development for Multiple System Atrophy, a rapidly progressive neurodegenerative disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results